137 related articles for article (PubMed ID: 17118522)
1. Distinguishing benign and malignant pelvic masses: the value of different diagnostic methods in everyday clinical practice.
Engelen MJ; Bongaerts AH; Sluiter WJ; de Haan HH; Bogchelman DH; Tenvergert EM; Willemse PH; van der Zee AG
Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):94-101. PubMed ID: 17118522
[TBL] [Abstract][Full Text] [Related]
2. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
4. An improved risk of malignancy index in diagnosis of adnexal mass.
Wang LM; Song H; Song X; Zhou XB
Chin Med J (Engl); 2012 Feb; 125(3):533-5. PubMed ID: 22490416
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance evaluation of adnexal masses.
Guerra A; Cunha TM; Félix A
Acta Radiol; 2008 Jul; 49(6):700-9. PubMed ID: 18568564
[TBL] [Abstract][Full Text] [Related]
6. The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.
Booth SJ; Turnbull LW; Poole DR; Richmond I
BJOG; 2008 Jun; 115(7):894-901. PubMed ID: 18485169
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models.
Mol BW; Boll D; De Kanter M; Heintz AP; Sijmons EA; Oei SG; Bal H; Brölmann HA
Gynecol Oncol; 2001 Feb; 80(2):162-7. PubMed ID: 11161854
[TBL] [Abstract][Full Text] [Related]
8. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index.
Enakpene CA; Omigbodun AO; Goecke TW; Odukogbe AT; Beckmann MW
J Obstet Gynaecol Res; 2009 Feb; 35(1):131-8. PubMed ID: 19215560
[TBL] [Abstract][Full Text] [Related]
9. Validation of referral guidelines for women with pelvic masses.
Im SS; Gordon AN; Buttin BM; Leath CA; Gostout BS; Shah C; Hatch KD; Wang J; Berman ML
Obstet Gynecol; 2005 Jan; 105(1):35-41. PubMed ID: 15625139
[TBL] [Abstract][Full Text] [Related]
10. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
Timmerman D; Van Calster B; Jurkovic D; Valentin L; Testa AC; Bernard JP; Van Holsbeke C; Van Huffel S; Vergote I; Bourne T
J Clin Oncol; 2007 Sep; 25(27):4194-200. PubMed ID: 17698805
[TBL] [Abstract][Full Text] [Related]
11. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
12. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
14. Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol.
Van Calster B; Timmerman D; Valentin L; McIndoe A; Ghaem-Maghami S; Testa AC; Vergote I; Bourne T
BJOG; 2012 May; 119(6):662-71. PubMed ID: 22390753
[TBL] [Abstract][Full Text] [Related]
15. [MR in the characterization of benign ovarian masses].
Torricelli P; De Santis M; Montanari N; Romagnoli R
Radiol Med; 1993 Jun; 85(6):816-26. PubMed ID: 8337440
[TBL] [Abstract][Full Text] [Related]
16. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
Dora SK; Dandapat AB; Pande B; Hota JP
J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses.
Inan N; Arslan A; Akansel G; Anik Y; Balci NC; Demirci A
Eur J Radiol; 2008 Jan; 65(1):154-62. PubMed ID: 17466481
[TBL] [Abstract][Full Text] [Related]
18. Triage of ovarian masses.
Chia YN; Marsden DE; Robertson G; Hacker NF
Aust N Z J Obstet Gynaecol; 2008 Jun; 48(3):322-8. PubMed ID: 18532966
[TBL] [Abstract][Full Text] [Related]
19. Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review.
Bazot M; Daraï E; Nassar-Slaba J; Lafont C; Thomassin-Naggara I
J Comput Assist Tomogr; 2008; 32(5):712-23. PubMed ID: 18830100
[TBL] [Abstract][Full Text] [Related]
20. MR imaging of the female pelvis: current perspectives and review of genital tract congenital anomalies, and benign and malignant diseases.
Patel VH; Somers S
Crit Rev Diagn Imaging; 1997 Oct; 38(5):417-99. PubMed ID: 9391749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
